Animal Rules: The Island Pharmaceuticals Story (ILA)

Good morning, Armchair Army,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

There are two questions that every stock needs to answer to make for a good investment story.

Why should I care?

AND

How is this going to make money?

Surprisingly, for many early-stage biotech companies, the answer is not immediately obvious.

I think this is due, in part, to the fact that biotech companies are NOT cash-earners… but cash burners.

Couple this with the long timeframes to realise value (and the binary nature of trial results), and the investments become tricky.

BUT the companies that can answer those two questions are put in a very good position.

Why should I care? How is this going to make money?

That is the strength of the next company in my Biotech 165 Challenge.

It has done very well at communicating the pathway to value without the typical biotech timeframes.

NOT the typical 20+ year development cycle. 

NOT a typical approval process.

NOT a typical commercialisation strategy.

Honestly, it feels like cheating.

… it’s not.

The next company on my Biotech 165 Challenge is…

Island Pharmaceuticals (ASX: ILA | MC: $133M | Cash: ~$14M | Not Held).

Island is developing an antiviral for outbreaks and national defence against bioweapons.

It has approval to deploy its drug in Uganda (against the current Ebola outbreak) and is running an animal trial to obtain approval for Marburg Disease.

Two pathways to approval, BOTH much quicker than the typical biotech timeframe.

The prize?

Government stockpiling contracts and an immediate US$200 million Priority Review Voucher for either indication approved.

The most un-biotech biotech on the ASX.

To take a drug through to FDA registration is a 20+ year journey.

Preclinical Studies. Phase 1 (safety). Phase 2 (efficacy). Phase 3 (registration).

THEN, once you have a drug approved, it is all about getting the drug to patients, sales and reimbursement.

There are many catalysts along that journey.

(and as you get closer to registration, the company generally will appreciate in value)

But what if you could get all the way to the end on a much shorter timeline?

No Phase 2. No Phase 3.

Registration on animal trials and human safety data alone.

… with an asset worth US$200 million on each newly registered drug.

NOT a typical drug development cycle.

NOT a typical approval process.

NOT a typical commercialisation strategy.

NOT your typical biotech company.

The most un-biotech biotech on the ASX… 

The next company on my Biotech 165 Challenge, Island Pharmaceuticals (ASX: ILA).

It sounds like a shortcut…

Skipping Phase 2 and Phase 3 clinical trials.

But there is a very good reason.

Sometimes, infections are so dangerous and so deadly that it would be unethical to run a clinical trial to find a treatment or a cure.

… and when there is a viral outbreak (like what is happening with Ebola in Africa right now), an experimental drug is the only solution.

Public health systems need defences against deadly viral outbreaks.

And there are ways to get promising drugs approved quickly.

Skip human trials; use animal models (non-human primates) to validate a drug's efficacy against deadly viral infections.

No Phase 2. No Phase 3.

Island is right now using the Animal Rule to get its drug approved for Marburg Disease, and this pathway has been validated by the US FDA.

While there is no officially defined term as an “Outbreak Approval”...

In previous Ebola outbreaks, drugs have been approved and fast-tracked based on a single Phase 3 clinical trial conducted in real time during an outbreak.

In the last Ebola outbreak, there was a Phase 3 trial called PALM, in which patients were dosed at a 1:1:1:1 ratio of four different potential solutions.

The winners quickly emerged and were fast-tracked for approval.

Earlier this week, Island was approved to deploy its drug in an active outbreak in Uganda involving the Bundibugyo strain of the Ebola virus.

It will start dosing patients live in an active outbreak situation later this year.

So… What’s the prize at the end of it all?

A Priority Review Voucher (essentially a ‘thank you’ from the government), which is a tradeable asset worth ~US$200 million.

Stockpiling Contracts: the last two drugs approved for Ebola Virus secured stockpiling contracts totalling ~US$1 billion.

As I said… not your typical biotech company.

Island’s drug is a broad-based antiviral called Galidesivir.

It was acquired from NASDAQ-listed BioCryst Pharmaceuticals (NASDAQ: BCRX) in early 2025.

At least US$70 million has been spent on the drug's development, with key government agencies including BARDA.

It was first developed to combat Hepatitis C in the early 2010s, but it soon became clear it was effective against a broad range of viral infections:

Over the following decade, BioCryst ran multiple animal trials to evaluate Galidesivir against different viruses:

BioCryst also conducted multiple Phase 1 safety trials in humans, which showed the drug was safe and well tolerated across different doses.

And while BioCryst ran the trials, they were predominantly funded by the US government:

More than US$70M in prior US government-funded development, all up.

In 2020, amid the COVID-19 pandemic, all infectious disease research was redirected toward finding a cure for COVID-19…

And you bet that BioCryst wanted to see if Galidesivir would work on COVID-19.

(It didn’t, but it did get some valuable human safety data from the trial).

So why did BioCryst let go of this drug?

Around this time, BioCryst was achieving very promising results in another clinical trial and dedicated all its resources to developing rare-disease therapeutics.

Last month, BioCryst said it would pause all internal drug discovery and development and pivot to a cost-saving partnership. (Source) 

This has left the door open for Island to be opportunistic…

Not only in acquiring Galidesivir, but also in acquiring some of the talent from BioCryst with the appointment of Raymond Taylor, who spent 19 years at BioCryst working with BARDA and NIAID on Galidesivir.

Galidesivir was on the shelf.

… and Island picked it up on the cheap.

It was the exact same strategy and playbook that the company has had since its IPO in 2021.

Find a de-risked asset with lots of data that a new company can breathe new life into.

… and so they did.

The acquisition was completed in 2025, and Island got right to work on bringing the drug to the clinic.

But here, the clinic looks more like a zoo.

Normally, to prove a drug works, you dose sick humans and measure whether they get better against a placebo in a double-blind clinical trial. 

That's what Phase 2 and Phase 3 are for.

To test efficacy.

But you can't do that with the Marburg Virus.

You can't ethically infect healthy volunteers with a fever that kills up to 88% of the people who get it… just to see if your drug helps.

And you can't reliably run a trial in the wild either, because outbreaks are rare and chaotic, and they occur in places without clinical trial infrastructure.

So in 2002 the FDA created the Animal Rule.

Animal Rule = if human efficacy trials are unethical or infeasible, the FDA will accept animal efficacy data to approve the drug.

Provided the animal model faithfully mimics the human disease, combined with human safety data and pharmacology to bridge the two.

It's the pathway used for smallpox, anthrax, and other bioterror threats.

Earlier this year, the FDA confirmed Island could use the animal rule to approve Galidesivir for Marburg Disease.

It laid out a two-stage pathway. 

Stage 1 is a dose-optimisation, pharmacokinetics and time-to-dose study in a small number of non-human primates (basically monkeys), using ILA's first manufactured batch of drug. 

Stage 2 is the pivotal, confirmatory efficacy study.

(Island is at the start of Stage 1 right now)

The work is being done at the Texas Biomedical Research Institute, the only private-sector Biosafety Level 4 lab in the United States, in collaboration with USAMRIID, the US Army's infectious disease research arm.

Island already has strong animal data showing survival with Galidesivir:

Island will still need to replicate these results to secure approval for the drug.

There are no guarantees here, and the clinical trial risk is real.

(The drug still needs to work)

But Marburg Virus isn’t the only virus that Galidesivir has shown to be effective against.

… there is an outbreak happening right now for Ebola, and Galidesivir just got the green light to be used in an active viral outbreak.

Since March 2026, there's been an Ebola outbreak in the Democratic Republic of Congo, spreading into Uganda.

1,500+ confirmed cases and 500+ deaths.

… basically 1 in 3.

(I couldn’t find a headline with the updated numbers this morning… but here is one from only two weeks ago. Just goes to show how fast things are spreading)

The World Health Organisation has declared it a Public Health Emergency of International Concern. 

That is the WHO’s equivalent of DEFCON 1. 

It's one of the largest Ebola outbreaks on record and the second-largest ever seen in the DRC.

Because the Bundibugyo strain is ~30% genomically divergent from Zaire (the last strain of Ebola), neither of the two existing Ebola treatments has confirmed efficacy.

So the world entered this outbreak with no approved therapeutic at all. 

Earlier this week, Island got the green light from the Ugandan Ministry of Health and the World Health Organisation to deploy Galidesivir into Uganda:

What this means (for Island) is that it will be able to collect real human data on the effectiveness of its drug.

Galidesivir has already shown efficacy against Ebola in animal models:

100% survival when dosed at 48 hours post-infection, and 67% survival even when treatment was delayed to three days.

The company presented this news on Wednesday:

The World Health Organisation launched the PARTNERS trial with MBP-134 and Remdesivir.

So there are currently two horses in the race for approval.

… but no guarantees that these antivirals are effective.

So, Galidesivir is emerging as a third option. 

Particularly if there are early, promising signs of efficacy in Uganda.

The drugs will speak for themselves.

And if people in Uganda are taking Galidesivir and suddenly not dying, I imagine that things will move quickly to either move Galidesivir onto the PARNERS trial or find another rapid approval pathway.

Like what happened with other Ebola drugs during the last viral outbreak.

Either way, Island gets to throw its hat in the ring as a potential candidate for what I’d call “Outbreak Approval”.

Outbreak Approval = A fast-tracked approval of an antiviral drug for use in a real-world outbreak with no known cure.

If Galidesivir is approved through this pathway (or the Animal Rule), what then?

Island is not the typical drug developer.

It doesn’t have to sell into hospitals or find patient populations… reimbursement or anything like that.

It has one customer. The government.

Governments will want to secure and stockpile antiviral drugs to defend against outbreaks and bioweapons.

To get an idea of what these stockpiling contracts are worth, Island has put together a table of historical deals:

Contracts range from US$100 million to US$1.2 billion in sales.

Each year, the government sets aside a budget to stockpile antiviral drugs.

Marburg is the only Category A bioterror threat for which no treatment is available in the Strategic National Stockpile.

This is the second pathway to commercial value for Island.

A Priority Review Voucher (PRV) is a reward the FDA hands out when a company gets a drug approved for certain neglected or high-consequence diseases.

Essentially a “thank you” from the government for creating defences against these types of diseases.

Both the Marburg and the Ebola programs are eligible for Priority Review Vouchers under the Tropical Disease PRV program.

The voucher itself shortens the FDA's review clock for future drugs from the standard 10 months to 6 months.

Big Pharma will pay a lot for that “fast pass” to approval review.

The last three priority review vouchers sold for US$200M, setting a pretty consistent market price for the asset.

This PRV is transferable. You can sell it.

All that Island needs to do to get one is to secure FDA approval.

(I say all that Island needs to do… approvals are still not an easy feat. Even if there is a fast-tracked pathway)

But if approved…

No sales, no patients, no reimbursements.

An immediately tradable US$200M asset.

So, I’ve been following Island for about a year now.

It was an old client of mine at Next Investors (where I previously worked as an analyst).

I remember hearing the story for the first time, and it was only when the phrase bioweapon defence was used that our ears pricked up.

“National defence” had been a macro thematic we had been following for a very long time, and finding a biotech leveraged to it was interesting.

There are two questions that retail investors ask themselves about any company:

Why should I care…

How is this going to make money…

I think Island has done an excellent job answering both questions.

(Which is surprisingly hard to do as an early-stage biotech company)

Everyone who is involved in running the company has put their own money in.

As I mentioned, Island is…

NOT a typical drug development cycle.

NOT a typical approval process.

NOT a typical commercialisation strategy.

BUT a story that retail investors can quickly understand and see a pathway to value.

There is still a clinical risk; Galedisivir still needs to work.

But if it does, the pathway to value is swift and clear.

A big thank you to the Chairman, Jason Carroll, and the CEO, David Foster, for sharing the story with me.

See you all next week,

The Armchair Analyst

PS. A big thank you to everyone who signed up for the Armchair After Market event yesterday. Places are still open.

Mesoblast (ASX: MSB) announces Q4 net revenue of US$36 million and full-year revenue of US$115 million for Ryoncil. (MSB, Not Held)

🪑 Very good first 12-month sales results. Half-year guidance was US$110M - US$120M, so they are bang in the middle.

Sigma Healthcare (ASX: SIG) will release 5 billion shares from escrow on the 27th August, representing shares owned by the vendors of the Chemist Warehouse Group. (SIG, Not Held)

🪑 Big escrow unlock, about $14 billion and 43% of the share register. 

It was also reported in the AFR that the two Chemist Warehouse brothers are interested in selling up to 20% of their stake. That would be $1.6 billion. (AFR)

Entropy Neurodynamics (ASX: ENP) is granted an Australian Patent for novel psilocin in crystalline form. (ENP, Not Held)

The FDA has paused releasing new drug rejection letters after complaints from an ‘unnamed big pharma company’. (Fierce Biotech)

🪑 I understand the risk of releasing trade secrets… but I think releasing the Complete Response Letters provides the whole industry with a much better outlook and improves efficiency in getting drugs through.

I would prefer these get released.